Evidence map›Paper›PMID 40495244›Full record

ArticleJournal of ovarian research2025

Cryopreservation and transplantation of ovarian tissue as post-cancer tissue therapy and an activator of oogenesis.

Volodimir Isachenko, Bernd Morgenstern, Plamen Todorov, Evgenia Isachenko, Frank Nawroth, Maria Quassdorff, Mahmoud Salama, Nina Mallmann-Gottschalk, Markus Merzenich, Christine Skala and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Volodimir IsachenkoDepartment of Obstetrics and Gynecology, Medical Faculty, Cologne University, Cologne, Germany. v.isachenko@yahoo.com.
Bernd MorgensternDepartment of Obstetrics and Gynecology, Medical Faculty, Cologne University, Cologne, Germany.
Plamen TodorovInstitute of Biology and Immunology of Reproduction of Bulgarian Academy of Sciences (BAS), Sofia, Bulgaria.
Evgenia IsachenkoDepartment of Obstetrics and Gynecology, Medical Faculty, Cologne University, Cologne, Germany.
Frank NawrothAMEDES Facharzt-Zentrum für Kinderwunsch, pränatale Medizin, Endokrinologie und Osteologie GmbH, Hamburg, Germany.
Maria QuassdorffDepartment of Obstetrics and Gynecology, Medical Faculty, Cologne University, Cologne, Germany.
Mahmoud SalamaDepartment of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, Michigan, USA.
Nina Mallmann-GottschalkDepartment of Obstetrics and Gynecology, Medical Faculty, Duisburg-Essen University, Essen, Germany.
Markus MerzenichDepartment of Obstetrics and Gynecology, Medical Faculty, Cologne University, Cologne, Germany.
Christine SkalaDepartment of Obstetrics and Gynecology, Medical Faculty, Cologne University, Cologne, Germany.
Gohar RahimiMedizinisches Versorgungszentrum AMEDES für IVF- und Pränatalmedizin in Köln GmbH, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In a recent publication (Reprod. Biomed. Online, 2024) it was presented point of view that, for post-cancer patients, in vitro fertilization (IVF) is a more effective method than ovarian tissue cryopreservation (OTC). In their commentary, Andersen et al. (Reprod. Biomed. Online, 2024) present nine distinct arguments advocating for the use of OTC. We fully agree with all these points. In support of the clinical application of the OTC procedure, we introduce two additional arguments. First, the transplantation of cryopreserved ovarian tissue can be considered as a form of tissue therapy. Moreover, OTC inherently serves as an activator of oogenesis. Second, during tissue dissection prior to OTC, a significant number of germinal vesicle (GV) oocytes can be retrieved, matured to the metaphase II (MII) stage, cryopreserved, and later used in IVF procedures.

Indexed as

CryopreservationNeoplasmsOogenesisOvaryFemaleFertility PreservationFertilization in VitroHumansOocytesGV oocyte maturationHippo signaling disruptionHypoxiaIntracellular Ca²⁺ increaseLipid peroxidationOsmotic disruption of cellular membranesOvarian tissue cryopreservationReactive oxygen species (ROS) generation

Identifiers

PMID40495244
PMCPMC12150575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.